| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/09/2023 | -12.52% | Barclays | $25 → $36 | Upgrades | Underweight → Equal-Weight |
| 12/16/2022 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 08/04/2022 | -10.09% | Morgan Stanley | $40 → $37 | Maintains | Overweight |
| 07/21/2022 | -17.38% | Guggenheim | $41 → $34 | Maintains | Neutral |
| 06/22/2022 | -23.45% | Cannonball Research | → $31.5 | Downgrades | Buy → Neutral |
| 06/21/2022 | -2.79% | Evercore ISI Group | $50 → $40 | Maintains | Outperform |
| 06/14/2022 | -0.36% | JP Morgan | $54 → $41 | Maintains | Overweight |
| 06/14/2022 | -2.79% | Morgan Stanley | $56 → $40 | Maintains | Overweight |
| 06/14/2022 | -39.25% | Barclays | $30 → $25 | Maintains | Underweight |
| 12/06/2021 | 21.51% | Wolfe Research | $54 → $50 | Downgrades | Outperform → Peer Perform |
| 11/02/2021 | 57.96% | Morgan Stanley | $60 → $65 | Maintains | Overweight |
| 02/05/2021 | 45.81% | Morgan Stanley | $57 → $60 | Maintains | Overweight |
| 11/09/2020 | 16.65% | Evercore ISI Group | $45 → $48 | Upgrades | In-Line → Outperform |
| 10/14/2020 | 33.66% | Morgan Stanley | → $55 | Initiates Coverage On | → Overweight |
| 08/27/2020 | 43.38% | Wolfe Research | → $59 | Initiates Coverage On | → Outperform |
| 06/15/2020 | 21.51% | JP Morgan | $42 → $50 | Maintains | Overweight |
| 05/06/2020 | -7.65% | CFRA | $40 → $38 | Upgrades | Hold → Buy |
| 04/23/2020 | -22.24% | Evercore ISI Group | → $32 | Downgrades | Outperform → In-Line |
| 04/15/2020 | 2.07% | JP Morgan | $44 → $42 | Maintains | Overweight |
| 02/06/2020 | -2.79% | CFRA | $35 → $40 | Maintains | Hold |
| 10/09/2019 | -33.17% | Guggenheim | → $27.5 | Initiates Coverage On | → Neutral |
| 12/14/2018 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/06/2018 | -56.26% | Barclays | $20 → $18 | Downgrades | Equal-Weight → Underweight |
| 04/30/2018 | — | JP Morgan | Upgrades | Neutral → Overweight |
What is the target price for New York Times (NYT)?
The latest price target for New York Times (NYSE: NYT) was reported by Barclays on February 9, 2023. The analyst firm set a price target for $36.00 expecting NYT to fall to within 12 months (a possible -12.52% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for New York Times (NYT)?
The latest analyst rating for New York Times (NYSE: NYT) was provided by Barclays, and New York Times upgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for New York Times (NYT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of New York Times, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for New York Times was filed on February 9, 2023 so you should expect the next rating to be made available sometime around February 9, 2024.
Is the Analyst Rating New York Times (NYT) correct?
While ratings are subjective and will change, the latest New York Times (NYT) rating was a upgraded with a price target of $25.00 to $36.00. The current price New York Times (NYT) is trading at is $41.15, which is out of the analyst's predicted range.